Kidney malignant
tumor is a type of primary
renal cell carcinoma, and mainly refers to
renal cancer. The
incidence of
kidney cancer and the number of
hospital cases in
China have been increasing. Based on the
clinical medicine information of
patients in the
hospital information system(HIS) database of 37
hospitals in
China, the combined medication of
patients with
kidney malignant
tumor were analyzed by Tabu search
algorithm, so as to analyze the combined medication of
patients with
kidney malignant
tumor in real world. A total of 7 095
patients with
kidney malignant
tumor were included, the ratio of
males to
females was 2.11∶1, and the ratio of
male patients increased gradually with age. About 3 933
patients(55.43%) showed a superior effect among those
patients. The common
therapies of
patients with
kidney malignant
tumor were anti-
tumor therapies and symptomatic
therapies, including anti-
infection,
regulation of
electrolyte balance, sedation and
analgesia,
analgesic,
regulation of gastrointestinal function. The whole
population of
patients with
kidney malignant
tumor were mostly treated with anti-
tumor drugs combined with more symptomatic
therapies, while the anti-
tumor therapies of the superiority
population of
patients were less combined with other
drugs, with less combined medication. The result may be related to the stage of
tumor or individual response to the
therapeutic regimen. No matter for the whole
population or for the superiority
population of
patients with
kidney malignant
tumor, the
therapies was mainly Western medicines. Based on the pathogenesis of
deficiency in origin and excess in superficiality with
kidney malignant
tumor,
Chinese subgroups with formula for clearing
heat and removing
toxicity, formula for vigorate
Qi and replenish the
blood, formula for regulate
Qi and invigorate the
blood,
laxative and
hemostatic were more commonly used. In the
future, further studies shall be conducted for combined
therapies for
patients of different stages, so as to
play the advantages of multi-target, overall
regulation,
toxicity reduction and
efficacy enhancement of
traditional Chinese medicine, improve the
life quality of
patients with
kidney malignant
tumor, prolong their
life time, and improve the
survival rate of
patients.